$PHAT News

Phathom Pharmaceuticals Provides Update on FDA Litigation

PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity

Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA

Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026

Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026

Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14;

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD

PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival

Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case

Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

Phathom Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

Phathom Pharmaceuticals Q2 Earnings Call Highlights